Suchergebnisse - "Gupta, Neeraj"

PubPharm (7)

1

Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma

enthalten in: British journal of haematology | 2019

von Kumar, S. | Grzasko, N. | Delimpasi, S. | +9

2

All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

enthalten in: European journal of cancer (Oxford, England : 1990) | 2019

von Dimopoulos, M. | Grosicki, S. | Jędrzejczak, W. | +10

3

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

enthalten in: Haematologica | 2018

von San-Miguel, J. | Echeveste Gutierrez, M. | Špicka, I. | +13

4

Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma

enthalten in: British journal of haematology | 2018

von Richardson, P. | Hofmeister, C. | Rosenbaum, C. | +15

5

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma : Clinical and Model-Based Analyses

enthalten in: Targeted oncology | 2017

von Gupta, N. | Yang, H. | Hanley, M. | +6

6

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

enthalten in: Blood | 2017

von Sanchorawala, V. | Palladini, G. | Kukreti, V. | +12

ErratumIn: Blood. 2020 Mar 26;135(13):1071. - PMID 32219354

7

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma : an open-label phase 1/2 study

enthalten in: The Lancet. Oncology | 2014

von Kumar, S. | Berdeja, J. | Niesvizky, R. | +16

CommentIn: Lancet Oncol. 2014 Dec;15(13):1417-8. - PMID 25456357

1
[1]